Yong Hannah Wen, MD, PhD

Hannah Yong Wen, MD, PhD

Pathologist

My Role at MSK

Areas of Expertise

My Specialties

  • Breast Pathology
  • Oncologic Pathology

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.
English
Share

About Me

What I Do at MSK
  • Director, Breast Pathology Fellowship
Get To Know Me

As a board-certified pathologist with a specialization in breast pathology, I perform microscopic examination of breast biopsies and surgical specimens and make diagnoses that help guide treatment decisions for our patients. I am proud to be part of the multidisciplinary team providing breast cancer patients with comprehensive and coordinated care.

Read more

I am interested in the molecular and genetic mechanisms of breast cancer development, progression, and response to treatments. My current research is focused on triple negative breast carcinoma — a subgroup of breast cancer that does not express estrogen and progesterone receptors, or the human epidermal growth factor receptor 2 (HER2). I also work closely with my colleagues from surgery, medical oncology, and radiation oncology on a variety of clinical studies in breast cancer.

My Role at MSK

A pathologist is a doctor who uses a microscope to make a diagnosis from cell and tissue samples. They analyze the samples to learn the cause and effects of a health condition.

Areas of Expertise

My Specialties

  • Breast Pathology
  • Oncologic Pathology
Education & Honors

Education

  • MD, Beijing Medical University (China)
  • PhD, University of Texas MD Anderson Cancer Center

Residencies

  • NYU Medical Center

Fellowships

  • Memorial Sloan Kettering Cancer Center

Board Certifications

  • Anatomic Pathology
  • Clinical Pathology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Aetna

In Network Coverage Type
HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (MTA retirees only)

In Network Coverage Type
PPO

Blue Cross Blue Shield Federal Employee Program

In Network Coverage Type
HMO, PPO

Blue Cross Blue Shield New York

In Network Coverage Type
PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

In Network Coverage Type
HMO, EPO PPO, POS

Blue Cross Health Plus

In Network Coverage Type
HMO

Carrum Health

In Network Coverage Type
Supplemental

Cigna

In Network Coverage Type
PPO, POS, HMO

Connecticare

In Network Coverage Type
POS, EPO, HMO

Emblem

In Network Coverage Type
PPO, POS, EPO, HMO

Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.

Emblem Essential

In Network Coverage Type
HMO

Emblem Medicare Advantage (Medicare Choice PPO Network and VIP Prime Network Only)

In Network Coverage Type
PPO, HMO

Empire Blue Cross Medicare Advantage

In Network Coverage Type
PPO, HMO, DSN

Empire Essential

In Network Coverage Type
HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

In Network Coverage Type
PPO

Fidelis

In Network Coverage Type
HMO, EPO

Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.

Fidelis Managed Medicaid & HARP

In Network Coverage Type
HMO

Fidelis Medicare Advantage

In Network Coverage Type
HMO

First Health

In Network Coverage Type
PPO

Healthfirst

In Network Coverage Type
EPO, HMO, PPO, POS

Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.

Healthfirst Managed Medicaid

In Network Coverage Type
HMO

Healthfirst Medicare Advantage

In Network Coverage Type
HMO, PPO

Healthsmart

In Network Coverage Type
PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

In Network Coverage Type
HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

In Network Coverage Type
PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

In Network Coverage Type
EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

In Network Coverage Type
EPO

Horizon Medicare Advantage

In Network Coverage Type
PPO, HMO

Husky CT Medicaid

In Network Coverage Type
State Government

Magnacare

In Network Coverage Type
PPO, POS, EPO

Straight NJ Medicaid

In Network Coverage Type
State Government

Straight NY Medicaid

In Network Coverage Type
State Government

Medicare Part A&B (traditional Medicare)

In Network Coverage Type
Federal Government

Multiplan/Beech Street/PHCS

In Network Coverage Type
Supplemental

MVP

In Network Coverage Type
PPO/OAP

Non-Participating Plans with Out of Network Benefits

In Network Coverage Type
PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

In Network Coverage Type
TBD

Oscar

In Network Coverage Type
HMO/EPO

Oxford

In Network Coverage Type
PPO, EPO

World Trade Center Health Program (WTC)

In Network Coverage Type
State Government

Qualcare

In Network Coverage Type
PPO, POS, HMO

Tricare

In Network Coverage Type
PPO, HMO

UMR

In Network Coverage Type
PPO, POS

United Healthcare

In Network Coverage Type
PPO, POS, HMO

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Request an Opinion

Current Patients

Request an appointment by logging on to MyMSK or calling your doctor’s office. If you aren’t registered for MyMSK, call 646-227-2593 for your Enrollment ID.

Contact and Location

Dr. Wen sees patients at one location.

Office Phone
Location
New York, NY
1275 York Avenue New York NY 10065

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Breast Pathology doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Wen Y and Liu B. The role of platelet activating factor in reproduction. Progress of Anatomical Sciences (China).  1996; 2: 204-211

Wen Y and Liu B.  Transforming growth factor a and its receptor in reproduction process. Medical Sciences (China). 1997; 16: 27-30

Wen Y and Liu B.  The expression of transforming growth factor a in the mouse embryos and preimplantation uterus.  J. Beijing Medical. University.  1997; 29:12-14

Read more

Yan DH, Wen Y, Spohn B, Choubey D, Gutterman J U, and Hung MC Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202.  Oncogene 1999; 18: 807-811

Wen Y, Yan DH, Spohn B, Deng J, Lin SY, and Hung MC.  Tumor suppression and sensitization to tumor necrosis factor a-induced apoptosis by an interferon inducible protein, p202, in breast cancer cells.  Cancer Res. 2000; 60:42-46

Lin SY, Xia W, Wang J, Kwong KY, Sphon B, Wen Y, Pestell R, and Hung MC.  b-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression.  Proc.Natl. Acad. Sci. U.S.A. 2000; 97: 4262-4266

Wen Y, Hu M, Makino K, Spohn, B, Bartholomeusz G, Yan DH, and Hung MC.  HER-2/neu promotes androgen-independent progression of prostate cancer cells through the Akt pathway.  Cancer Res. 2000; 60:6841-6845

Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, and Hung MC.  Nuclear localization of EGF receptor and its potential new role as a transcriptional factor.  Nature Cell Biology 2001; 3:802-808

Wen Y, Yan DH, Spohn B, Xie K, Wang B, Shao R, Ding Y, and Hung MC.  p202, an interferon-inducible protein, mediates anti-tumor activity in human pancreatic cancer cells.  Cancer Res. 2001; 61:7142-7147

Zou Y, Peng H, Zhou B, Wen Y, Wang SC, Tsai EM, and Hung MC.   Systemic tumor suppression by the proapoptotic gene bik. Cancer Res. 2002; 62: 8-12

Lee WP, Wen Y, Varnum B, and Hung MC. Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis.  Oncogene 2002; 21:329-336

Ding Y, Wen Y, Spohn B, Wang L, Xia W, Kwong KY, Shao R, Li Z, Hortobagyi G, Hung MC, and Yan DH.  Proapoptotic and Antitumor Activities of Adenovirus-mediated p202 Gene Transfer. Clin Cancer Res 2002; 8:3292-3297

Deng J, Miller SA, Wang HY, Xia W, Wen Y, Zhou BP, Li Y, Lin SY, and Hung MC. Beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer.  Cancer Cell 2002; 2:323-334

Yan DH, Abramian A, Li Z, Ding Y, Wen Y, Liu TJ, and Hunt K.  p202, an Interferon-Inducible Protein, Inhibits E2F1-Mediated Apoptosis in Prostate Cancer Cells.   Biochemical and biophysical research communications (BBRC) 2003; 303: 219-222

Li Y, Wen Y, Zhou BP, Kuo HP, Ding Q, and Hung MC.  Enhancement of Bik Anti-Tumor Effect bu Bik Mutant.  Cancer Res. 2003; 63:7630-7633

Wen Y, Giri D, Spohn B, Zinner RG, Xia W, Thompson TC, Matusik RJ, Zou Y, Yan DH, and Hung MC.  Prostate Specific Anti-tumor Activity by Probasin Promoter-Directed p202 Expression.  Mol. Carcinogenesis 2003; 37:130-137

Deng J, Xia W, Miller SA, Wen Y, Wang HY, and Hung MC.  Crossregulation of NF-kappa B by the APC/GSK beta/beta-catenin pathway.  Mol. Carcinog. 2004; 39:139-146

Yan DH*, Wen Y*, Su LK, Xia W, Wang SC, Zhang S, Gan L, Hortobagyi GN, and Hung MC.  A delayed chemically-induced tumorigenesis in Brca2 mutant mice.  Oncogene 2004; 23:1896-1901   (equal contribution)

Shao R, Lee DF, Wen Y, Ding Y, Xia W, Ping B, Yagita H, Spohn B, and Hung MC.  E1A Sensitizes Cancer Cells to TRAIL-Induced Apoptosis through Enhancement of Caspase Activation.  Molecular Cancer Res. 2005; 3:219-226

Cha TL, Lin Q, Chen CT, Wen Y, and Hung MC.  Emodin Induces Androgen Receptor Degradation and Suppresses Prostate Cancer Cell Growth.  Cancer Res. 2005; 65: 2287-2295

Wen YH, Koeppen H, Garcia R, Chiriboga L, Tarlow B, Peters B, Eigenbrot C, Yee H, Steiner G, and Greco MA.  Epidermal Growth Factor in Osteosarcoma: Expression and Mutational Analysis. Human Pathol 2007; 38:1184-1191

Wen YH, Giashuddin S, Shapiro RL, Velazquez FE, and Melamed J.  Unusual Occurrence of a Melanoma with Intermixed Epithelial Component: A True melanocarcinoma? Case Report and Review of Epithelial Differentiation by Light Microscopy and Immunohistochemistry.  Am J Dermatopathol 2007; 29:395-399

Wen YH, Shi X, Chiriboga L, Matsahashi S., Yee H, and Afonja O.  Alterations in the expression of PDCD4 in ductal carcinoma of the breast.  Oncology report 2007; 18:1387-1393

Rapkiewicz A, Wen YH, Sen F, Das K. Cytomorphologic examination of anaplastic large cell lymphoma by fine-needle aspiration cytology. Cancer. 2007; 111:499-507

Morris LG, Wen YH, Nonaka D, Kutler DI, Huan Y, and Wang B.  PNL2 melanocytic marker in immunohistochemical evaluation of primary mucosal melanoma of the head and neck.  Head Neck. 2008;30:771-775

Wen YH, Yee H, Goswami S, Shukla P.  Fascin Expression in Serous Tumors of Ovary Correlates with Aggressiveness of Malignancy.  Int J Gynecol Cancer 2009; 28:187-192

Flavin R, Smyth P, Barrett C, Russell S, Wen YH, Wei J, Laios A, O’Toole S, Ring M, Denning K, Li J, Aherne S, Sammarae D, Aziz NA, Alhadi A, Finn SP, Loda M, B S, Sheils O, O’Leary JJ.  mir-29b expression is associated with disease-free survival in ovarian serous carcinoma patients.  Int J Gynecol Cancer 2009; 19: 641-647

Peng L, Wen Y, Han Y, Wei A, Shi G, Mizuguchi M, Lee P, Hernando E, Mittal K, and Wei JJ. Expression of Insulin-Like Growth Factors (IGFs) and IGF Signaling: Molecular Complexity in Uterine Leiomyomas. Fertil Steril 2009; 91:2664-2675

Chandra P, Wen YH, Tuli S, Raphael BG, Amorosi EL, Medeiros LJ, and Ibrahim S.  Post-Chemotherapy Histiocyte-rich Pseudotumor Involving the Spleen.  Am J Clin Pathol.  2009; 132: 342-348

Wang S, Yee H, Wen YH, Wang BY.  Papillomas of the External Ear Canal: Report of Ten Cases in Chinese Patients with HPV In Situ Hybridization.  Head Neck Pathol. 2009; 3:207-211

Wolf JH, Wen YH, Axelrod D, Roses D, Guth A, Shapiro R, Cohen J, Singh B.  Higher Volume at Time of Breast Conserving Surgery Reduces Re-excision in DCIS.  Int J Surg Oncol. 2011; 2011:785803. Epub 2011 Mar 9

D’Arcy C, Wen YH, Stadler ZK, Brogi E, Shia J.  Synchronous breast cancers with different morphologic and molecular phenotypes occurring in Lynch syndrome: what does the heterogeneity imply? Am J Surg Pathol. 2011; 35:1743-1748

Ho AY, Gupta G, King TA, Perez CA, Patil SM, Rogers KH, Wen YH, Brogi E, Morrow M, Hudis CA, Traina T, McCormick B, Powell SN, Robson ME. Favorable Prognosis in Patients with T1a/T1bN0 Triple Negative Breast Cancers Treated With Multimodality Therapy. Cancer 2012; 118: 4944-4952

Wen YH, Ho A, Patil S, Akram A, Catalano J, Norton L, Benezra R, Brogi E.  Id4 Protein is Highly Expressed in Triple Negative Breast Carcinomas: Possible Implications for BRCA1 Downregulation. Breast Cancer Res Treat. 2012; 135: 93-102

Wen YH, Brogi E, Zeng Z, Akram M, Catalano J, Paty P, Norton L, Shia J.  DNA Mismatch Repair Deficiency in Breast Carcinoma:  a Pilot Study of Triple Negative and non-Triple Negative Tumors. Am J Surg Pathol. 2012; 36:1700-1708

Zhang X, Jin X, Malladi S, Zou Y, Wen YH, Brogi E, Smid M, Foekens J, and Massagué J. Selection of Bone Metastasis Seeds by Mesenchymal Signals in the Primary Tumor Stroma. Cell 2013; 154:1060-1073

Wen YH, Brogi E, Hasanovic A, Ladanyi M, Soslow R, Chitale D, Shia J, Moreira AL. Immunohistochemical staining with EGFR mutation specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma.  Modern Pathol. 2013; 26:1197-1203

Weigelt B, Ng CKY, Wen YH, Reis-Filho JS. Combining two antibodies to define E-cadherin loss of expression in non-lobular carcinomas: when less is more. Histopathology 2013; 63:439-440

Perez CA, Zumsteg Z, Gupta G, Morrow M, Arnold B, Patil SM, Traina TA, Robson ME, Wen YH, McCormick, B, Powell SN, Ho AY. Black race as a prognostic factor in triple negative breast cancer patients treated with breast conserving therapy: A large, single-institution retrospective analysis. Breast Cancer Res Treat. 2013; 139: 497-506

Sung JS, Jochelson MS, Brennan S, Joo S, Wen YH, Moskowitz C, Zheng J, Dershaw DD, Morris EA. MR Imaging Features of Triple Negative Breast Cancers.  Breast J. 2013; 19:643-649

Gupta GP, Vanness K, Barlas A, Manova-Todorova KO, Wen YH, and Petrini JHJ. The Mre11 Complex Suppresses Oncogene-driven Breast Tumorigenesis and Metastasis. Mol Cell 2013; 52:353-365

Schrader K, Stratton K, Murali R, Laitman Y, Cavallone L, Offit L, Wen YH, Thomas T, Shah S, Rau-Murthy R, Manschreck C, Salo-Mullen E, Otegbeye E, Corines M, Norton L, Hudis C, Klein R, Kauff N, Robson M, Stadler Z, Haber D, Lipkin S, Friedman E, Foulkes WD, Altshuler D, Vijai J, Offit K. Genome Sequencing of Multiple Primary Tumors Reveals Novel PALB2 Variant. J Clin Oncol.2016; 34: e61-67 Epub 2014 June 30

Weinreb I, Piscuoglio S, Martelotto LG, Waggott D, Ng CKY, Perez-Ordonez B, Harding NJ,  Alfaro J, Chu KC, Viale A,  Fusco N, da Cruz Paula A, Marchio C, Sakr RA, Lim R, Thompson LDR, Chiosea SI, Seethala RR, Skalova A, Stelow EB, Fonseca I, Assaad A, How C, Wang J, de Borja R, Chan-Seng-Yue M,  Howlett CJ, Nichols AC, Wen YH, Katabi N, Buchner N, Mullen L, Kislinger T, Wouters BG, Liu F , Norton L, McPherson JD , Rubin BP, Clarke BA, Weigelt B, Boutros PC, Reis-Filho JS. Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nature Genetics. 2014; 46:1166-1169

Tozbikian G, Brogi E, Kadota K, Catalano J, Akram M, Patil S, Ho AY, Reis-Filho JS, Weigelt B, Norton L, Adusumilli PS, Wen, HY*. Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-like Phenotype, Distant Metastases and Decreased Survival. PLoS ONE 2014; 9: e114900. (*corresponding author)

Piscuoglio S, Hodi Z, Katabi N, Guerini-Rocco E, De Souza Macedo G, Ng CKY, de Mattos Arruda L, Wen HY, Rakha EA, Ellis IO, Rubin BP, Weigelt B and Reis-Filho JR. Are acinic cell carcinomas of the breast and salivary glands distinct diseases? Histopathology 2015; 67:529-537

Kleppe M, Comen E, Wen, HY, Bastian L, Blum B, Rapaport FT, Keller M, Granot Z, Socci N, Viale A, You D, Benezra R, Weigelt B, Reis-Filho JS, Brogi E, Berger MF, Levine RL, Norton L. Leukocytes Infiltrating Primary Breast Cancers Harbor Oncogenic Mutations. NPG Breast Cancer 2015; 1: article number 15005

Martelotto LG, De Filippo MR, Ng CK, Natrajan R, Fuhrmann L, Cyrta J, Piscuoglio S, Wen HC, Lim RS, Shen R, Schultheis AM, Wen YH, Edelweiss M, Mariani O, Stenman G, Chan TA, Colombo PE, Norton L, Vincent-Salomon A, Reis-Filho JS, Weigelt B. Genomic Landscape of Adenoid Cystic Carcinoma of the Breast. J Pathol 2015; 237:179-189

Guerini-Rocco E, Piscuoglio S, Ng CKY, De Filippo MR, Geyer FC, Eberle CA Akram M, Fusco N, Ichihara S, Vincent-Salomon A, Ellis IO, Wen HY, Weigelt B, Schnitt SJ, and Reis-Filho JS. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harboring TP53 somatic mutations. J Pathol 2016; 238: 677-688

Ebbesen SH, Scaltriti M, Bialucha CU, Morse N, Kastenhuber ER, Wen HY, Dow LE, Baselga J, Lowe SW. PTEN loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. Proc Natl Acad Sci U S A. 2016; 113: 3030-3035

Weisman P, Ng  CKY, Brogi E, Eisenberg  R, Won  HH, Piscuoglio S, De Filippo MR, Ioris R, Akram M, Norton L, Weigelt B, Berger MF, Reis-Filho JS, and Wen HY*. Genetic Alterations of Triple Negative Breast Cancer By Targeted Next Generation Sequencing And Correlation With Tumor Morphology. Mod Pathol 2016; 29:476-488. (*corresponding author)

Qian XL, Wen HY, Yang YL, Gu F, Guo XJ, Liu FF, Zhang L, Zhang XM, Fu L. Assessment Of Dual-Probe Her-2 Fluorescent In Situ Hybridization In Breast Cancer By 2013 ASCO/CAP Guidelines Produces More Equivocal Results Than That By 2007 ASCO/CAP Guidelines. Breast Cancer Res Treat July 25, 2016; 159: 31-39. Epub ahead of print 2016 July 25

Tozbikian G, Brogi E, Vallejo CE, Giri D, Murray M, Catalano J, Olcese  C, Patil S, Van Zee KJ, Wen HY*. Atypical Ductal Hyperplasia Bordering on Ductal Carcinoma In Situ: Interobserver Variability and Outcomes in 105 Cases. Int J Surg Pathol 2016, July 31. Epub ahead of print (*corresponding author)

Wen HY, Krystel-­Whittemore M, Pareja F, Bowser ZL, Morrow M, Dickler M, Hudis C and Brogi E. Breast Carcinoma with Oncotype DX Recurrence Score Lower Than 18: Rate of Distant Metastases in a Large Series with Clinical Follow-up. Cancer. 2016, Aug 15. Epub ahead of print

McArthur HL, Diab A, Page D, Yuan J, Solomon SB, Sacchini V, Comstock C, Durack JC, Sung J, Maybody M, Ginsberg A, Wong P, Barlas A, Dong Z, Blum B, Patil S, Neville DA, Comen EA, Morris EA, Kotin A, Brogi E, Wen HY, Morrow M, Lacouture M, Sharma P, Allison JP, Hudis CA, Wolchok JD, and Norton L. A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. Clin Cancer Res 2016, Aug 26. Epub ahead of print

Page DB, Yuan J, Redmond D, Wen HY, Durack JC, Emerson R, Solomon S, Dong Z, Wong P, Comstock C, Diab A, Sung J, Maybody M, Morris EA, Brogi E, Morrow M, Sacchini V, Elemento O, Robins H, Patil S, Allison JP, Wolchok JD, Hudis C, Norton L, and McArthur H. T-cell Receptor DNA Deep Sequencing as a Biomarker of Clonality Expanded TILs in Breast Cancer After Immunotherapy. Cancer Immunol Res 2016; 4: 835-844. Epub ahead of print 2016 Sep 1

Geyer FC, Berman SH, Marchiò C, Burke K, Guerini-Rocco E,  Piscuoglio S, Ng CKY, Pareja F, Wen HY, Hodi Z, Rakha EA, Ellis IO, Schnitt S, Norton L, Weigelt B and Reis-Filho JS. Genetic Analysis of Microglandular Adenosis and Acinic Cell Carcinomas of the Breast Provides Evidence for the Existence of a Low-grade Triple-Negative Breast Neoplasia Family. Modern Pathol 2016, Oct 7. Epub ahead of print

Reviews

Zuo Z, Chandra P, Wen YH, Koeppen H.  Molecular Diagnosis of Acute Myeloid Leukemia.  Diagnostic Histopathology 2009; 15: 531-539

Wen YH, Weigelt B, and Reis-Filho JS.  Microglandular Adenosis: a Non-Obligate Precursor of Triple-Negative Breast Cancer?  Histol Histopathol. 2013, 28:1099-1108

Ross DS, Wen YH, Brogi E.  Ductal Carcinoma in situ: Morphology-Based Knowledge and Molecular Advances. Adv Anat Pathol. 2013. 20:205-216

Weisman P and Wen HY. Commentary on “Impact of Analysis of Frozen-section Margin on Reoperation Rates In Women Undergoing Lumpectomy For Breast Cancer: Evaluation Of The National Surgical Quality Improvement Program Data”. Breast Disease: A Yearly Book Quarterly. 2015; 26:159

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Hannah Yong Wen discloses the following relationships and financial interests:

  • AstraZeneca
    Professional Services and Activities

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures